AU Stock MarketDetailed Quotes

TLX Telix Pharmaceuticals Ltd

Watchlist
  • 27.870
  • -1.090-3.76%
20min DelayNot Open Mar 4 16:00 AET
9.33BMarket Cap192.21P/E (Static)

Telix Pharmaceuticals Ltd Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Telix Pharmaceuticals Ltd FY2024 Annual Report Date

Currency：AUDFeb 20, 2025

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
778.04M
783.21M
+5.16M
Beat Est.
+54.82%
+55.85%
+0.66%
EPS
0.17
0.14
-0.03
Miss Est.
+964.60%
+798.14%
-15.64%
Analyst Rating
Strong Buy

Feb 25, 2025

Telix Pharmaceuticals Ltd Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: AUD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
Aug 23, 20232023/Q2120.700M / ----
Feb 27, 20232022/Q480.749M / 68.850M--
Oct 20, 20222022/Q355.300M / ----
DatePeriodRevenue/EstimateEarnings Call
Aug 23, 20232023/Q2120.700M / ----
Feb 27, 20232022/Q480.749M / 68.850M--
Oct 20, 20222022/Q355.300M / ----
--------
--------

Unlock Free Earnings Estimates

Telix Pharmaceuticals Ltd Earnings Reports

  • Telix Pharmaceuticals Ltd: Telix Announces Change in Reporting Currency to USD

    Feb 24 16:42 ET

  • Telix Pharmaceuticals Ltd: 2024 Full Year Results Presentation

    Feb 20 03:02 ET

  • Telix Pharmaceuticals Ltd: 2024 Full Year Results Announcement

    Feb 20 03:01 ET

  • Telix Pharmaceuticals Ltd: Appendix 4E and 2024 Annual Report

    Feb 20 03:00 ET

    • Read more

    Trending Stocks
    ASX High Dividend ASX High Dividend
    Symbol Div YieldTTM Dividend TTM
    Westpac Banking Corp
    WBC
    4.61% 1.47
    CommBank
    CBA
    2.95% 4.65
    Telstra Group Ltd
    TLS
    4.17% 0.18
    ANZ Group Holdings Ltd
    ANZ
    5.98% 1.77
    BHP Group Ltd
    BHP
    6.06% 2.39

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Feb 25, 2025

    Strong Buy

    • Strong Buy

      77.78%

    • Buy

      11.11%

    • Hold

      0.00%

    • Underperform

      11.11%

    • Sell

      0.00%

    Price Target

    No Data

    Investment Theme Healthcare - Cancer Research
    Healthcare - Cancer Research
    Intraday+0.47%